Skip to main content
US EQUITIES CLOSED CRYPTO 24/7
HALAL TRADING ROOM Sharia-screened signals
TERMINAL
ZN

ZNTLStock

Nasdaq Global Market · Healthcare · US

$1.49 last close 2026-11-17
Open in terminalCompare
Price alert

Verdicts genuinely change. Free email alert the moment ZNTL's does — no target price to set, unlike a price alert.

Stable Ratio screen, 0 of 7 decided standards passing. No standard's deciding ratio sits within 3 points of its line. What would change it

Sharia status
NOT COMPLIANT
Per our in-house ratio engine
0 of 7 pass our own screen — all 7 agree here
Purification 100.00% *
🕌Open research, not a fatwa — verify with your own scholar.

Trade setup

Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.

SEPARATE FROM SHARIAH
No trade setup shown — a stock that isn't cleanly Sharia-compliant never gets a bullish verdict here.

Why this signal?

The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.

Structure1 of 5 timeframes bullish · 95.7% aligned
VWAPPrice below VWAP ($1.70)
VolumeRelative volume 4.7× the 20-day average
Momentum10-day rate of change -16.3%

ZNTL is currently considered not halal (non-compliant), per our in-house ratio engine. See the full ratio breakdown and business-activity screen below for the reasoning.

⚠️ Financial ratios are only half the screen. A company whose core business is in an excluded sector — weapons/defense, alcohol, gambling, conventional (interest-based) finance, tobacco, pork, or adult entertainment — is non-compliant even if every debt and income ratio passes. So passing ratios below don't override this verdict; check the business-activity screen for the reason.

435 other Healthcare stocks pass this same screen. See compliant Healthcare stocks →

Market & analysts
Price target
$7.44
+399.6% · 9 analysts
Institutional own.
65.4%
of shares
Momentum (10d)
-16.3%
rate of change
SMC grade
D · 42
95.7% aligned
100.00% *
Purification ratio (secondary provider, uncertain)
D · 42
SMC grade — 95.7% timeframe alignment
-16.3%
Rate of change (10d)
$7.44
Price target (+399.6%) · 9 analysts
65.4%
Institutional ownership

🕌 In-house Compliance Research

Computed from published company financials, balance sheet as of 2026-09-30. These ratios come from the issuer's own published statements rather than structured SEC data.

AAOIFI divides by the market cap: $185.6M as of 2026-11-15.

Business activity: cleared (no excluded categories detected)

AAOIFI Fail 1 of 2 ratios pass
RatioValueThresholdResult
Interest-bearing debt 19.78% 30.00% Pass(10.2pp buffer)
Interest-bearing investments 124.77% 30.00% Fail(94.8pp over)
Usmani Fail 1 of 3 ratios pass
RatioValueThresholdResult
Interest-bearing debt 13.59% 33.00% Pass(19.4pp buffer)
Interest-bearing investments 85.69% 33.00% Fail(52.7pp over)
Non-liquid assets 14.31% at least 20.00% Fail(5.7pp below the floor)
MSCI Fail 1 of 2 ratios pass
RatioValueThresholdResult
Interest-bearing debt 13.59% 33.33% Pass(19.7pp buffer)
Cash + interest-bearing securities 85.69% 33.33% Fail(52.4pp over)
FTSE Fail 1 of 2 ratios pass
RatioValueThresholdResult
Interest-bearing debt 0.00% 33.33% Pass(33.3pp buffer)
Cash + interest-bearing securities 85.69% 33.33% Fail(52.4pp over)
Dow Jones Islamic Market Fail 1 of 2 ratios pass

Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 12.63% 33.00% Pass(20.4pp buffer)
Cash + interest-bearing securities 79.69% 33.00% Fail(46.7pp over)
S&P Shariah Unverified⚠️ a figure this standard divides by was not available, so it could not be scored — the rows below show what was and was not computed 2 of 2 ratios pass

Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 6.75% 33.00% Pass(26.2pp buffer)
Cash + interest-bearing securities 42.57% 49.00% Pass(6.4pp buffer)
MSCI M-Series Fail 1 of 2 ratios pass

Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 6.75% 33.33% Pass(26.6pp buffer)
Cash + interest-bearing securities 42.57% 33.33% Fail(9.2pp over)

Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.

How close is it to flipping?

Every current reading against its own line, closest first. A verdict is only as durable as that distance.

AAOIFI Standard 21 (% of market cap)debt ratio 10.2pts
Usmani (% of total assets)debt ratio 19.4pts
MSCI Islamic Index (% of total assets)debt ratio 19.7pts
AAOIFI Standard 21 (% of market cap)investments ratio 94.8pts
Usmani (% of total assets)investments ratio 52.7pts
MSCI Islamic Index (% of total assets)cash and interest ratio 52.4pts

The numbers the ratios are built from

Read from ZNTL's own filings. Every percentage on this page is one of these lines divided by another, so the inputs are shown rather than asserted.

LineFigureAs reportedRead from
RevenueTotal revenue for the period $0 2026-09-30 RevenueFromContractWithCustomerExcludingAssessedTax
Interest-bearing debtShort and long-term borrowings $0 2026-09-30 no debt tag reported in 3+ years (treated as $0)
Cash and interest-bearing securitiesCash, equivalents and marketable securities $231.5M 2026-09-30 CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents, AvailableForSaleSecuritiesDebtSecuritiesCurrent
Total assetsBalance sheet total $270.2M 2026-09-30 Assets
Market capDenominator for AAOIFI $185.6M live quote price x shares
36-month average market capDenominator for S&P Shariah and MSCI M-Series $334.8M 756 trading days closes x shares
24-month average market capDenominator for Dow Jones Islamic Market $178.2M 504 trading days closes x shares
Non-permissible revenueInterest and excluded income $0 2026-09-30 no interest-income tag reported in 3+ years (treated as $0)

Two dates, not one: a balance-sheet line and an income-statement line cover different windows by design, so each figure carries its own.

Sources

Filing information. Balance sheet as of 2026-09-30. Income statement as of 2026-09-30. Screened 2026-11-15.

A newer filing exists: our EDGAR watch has seen one since this screen and it is queued for re-screening. The figures below are from the filings named, not the newer one.

Filing links appear after the next screen: this row was screened before filing citations were recorded.

  • Total assets$270.2M
    Assets · balance sheet as of 2026-09-30
  • Interest-bearing debt$0
    no debt tag reported in 3+ years (treated as $0) · balance sheet as of 2026-09-30
  • Cash and interest-bearing securities$231.5M
    CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents, AvailableForSaleSecuritiesDebtSecuritiesCurrent · balance sheet as of 2026-09-30
  • Revenue$0
    RevenueFromContractWithCustomerExcludingAssessedTax · income statement as of 2026-09-30
  • Interest income (non-permissible)$0
    no interest-income tag reported in 3+ years (treated as $0) · income statement as of 2026-09-30
  • Market cap$185.6M
    Market-data quote at screen time, 2026-11-15 · not a filing figure, so no link

What changed, and when

Verdict history for ZNTL. A verdict that never moved is recorded too, so a quiet history reads as measured rather than missing.

  • 2026-11-15 Unverified → Fail filing re-screen

Tracked since 2026-09-07.

What would change the status

The headline verdict is the majority of the decided ratio standards — 0 pass and 7 fail of 7 — with a business-activity screen and any hold applied on top. Balance sheet as of 2026-09-30; market cap as stored on 2026-11-15.

No standard's deciding ratio sits within 3 points of its line.

The ratios that move with the share price

AAOIFI's debt ratio is $36.7M debt (operating leases included, as the screen counts it) over a market cap of $185.6M (as of 2026-11-15), 19.8% against a 30% line.

It would fail if the market cap fell to $122.4M (-34%), about $1.25 a share against $1.89 implied by the screen's own figures.

AAOIFI would then fail; the majority verdict would stay Not compliant (0 of 7 decided standards passing).

At the screen's market cap, debt would have to rise by $19.0M to reach the line.

AAOIFI would then fail; the majority verdict would stay Not compliant (0 of 7 decided standards passing, counting every standard that divides the same figure).

AAOIFI's investments ratio is $231.5M cash and interest-bearing investments over a market cap of $185.6M (as of 2026-11-15), 124.8% against a 30% line.

It would pass if the market cap rose above $771.7M (+316%), about $7.85 a share against $1.89 implied by the screen's own figures.

AAOIFI would then be unverified; the majority verdict would stay Not compliant (0 of 6 decided standards passing).

At the screen's market cap, it would take $175.9M less cash and interest-bearing investments to clear the line.

AAOIFI would then be unverified, and the majority verdict would move from Not compliant to no verdict (0 of 0 decided standards passing, counting every standard that divides the same figure).

Only AAOIFI divides by the market cap itself. The Dow Jones, S&P and MSCI M-Series standards divide by a 24- or 36-month average and the others by total assets, so a day's price move does not reach them. Figures are the screen's own; the live market cap differs from the stored one.

Shariah-compliant alternatives

Compliant companies in Biotechnology listed on the same market, largest first. Each is screened on its own; none carries a documented concern or a hold.

CompanyMarket capPrice, day
VRTXVertex Pharmaceuticals, Inc. $121.1B $534.20-0.67%
REGNRegeneron Pharmaceuticals, Inc. $85.3B —
ARGXArgen X SE - ADR $64.3B —
ONCBeOne Medicines Ltd. American Depositary Shares $40.4B —
ALNYAlnylam Pharmaceuticals Inc $31.6B —

A dash means no fresh quote is cached for that symbol; this list does not fetch one.

Funds that hold ZNTL

4 of the 203 funds whose filed holdings we currently hold own ZNTL shares. That set is a fixed list of widely held index funds and Shariah funds, plus the funds our look-through has read most recently. It is not every fund that owns ZNTL.

You may already own it

Widely held U.S. index funds. If you own one, you own ZNTL through it. None of them is a Shariah fund; the last column is our look-through of each.

FundZNTL in fundFund compliant by weight
VTI VANGUARD TOTAL STOCK MARKET INDEX FUND 0.00% 54%
Other funds
FundZNTL in fundFund compliant by weight
IWC iShares Micro-Cap ETF 0.05% 24%
ITWO ProShares Russell 2000 High Income ETF 0.01% 29%
DFUS Dimensional U.S. Equity Market ETF 0.00% 53%

Sorted by ZNTL’s share of each fund, from the fund’s latest SEC N-PORT filing. “Compliant by weight” is the share of the fund’s holdings our look-through screens compliant. A fund is listed only where its filing is mostly equity and names ZNTL once, so a bond is not counted as the shares. Shariah funds are those with a recorded certification, on our halal ETF list, or named Shariah, Islamic, Halal or Sukuk.

Tracked investors holding ZNTL
InvestorFirmPositionWeightAs of
Ken Griffin Citadel Advisors $13M 0.0% 2026-09-30
Peter Brown Renaissance Technologies $4M 0.0% 2026-09-30
Israel Englander Millennium Management $1M 0.0% 2026-09-30
David Shaw D. E. Shaw & Co. $1M 0.0% 2026-09-30
Jefferies Jefferies Financial Group $0M 0.0% 2026-09-30

From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.

6.615.283.962.631.302025-11-182026-05-202026-11-16

Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset

Support & Resistance
S3
1.50
S2
1.57
S1
1.63
PIVOT
1.70
R1
1.76
R2
1.83
R3
1.89

Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.

Price Forecast

The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.

7-day expected range
2.98 – 4.04
±15.18% from 3.51, made 2026-09-14 · resolves 2026-09-21
STRONG SELL
from 19 indicators
74.1% of our last 15548 forecasts — across every instrument we forecast, not just this one — landed inside their stated range, and 50.3% called the direction correctly.

Technical Summary

Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.

STRONG SELL
19 indicators
OscillatorsSTRONG BUY
5 buy · 0 neutral · 2 sell
Moving averagesSTRONG SELL
0 buy · 0 neutral · 12 sell
Every indicator, and what it reads
IndicatorValueSignal
RSI (14)29.40BUY
Stochastic %K (14)3.77BUY
CCI (20)-100.09BUY
Williams %R (14)-96.23BUY
MACD (12,26,9)0.02BUY
ROC (10)-13.51SELL
Momentum (10)-0.25SELL
EMA (10)1.77SELL
SMA (10)1.74SELL
EMA (20)1.93SELL
SMA (20)1.93SELL
EMA (30)2.11SELL
SMA (30)2.10SELL
EMA (50)2.45SELL
SMA (50)2.48SELL
EMA (100)2.91SELL
SMA (100)3.42SELL
EMA (200)2.92SELL
SMA (200)3.39SELL

About ZNTL

Healthcare · Biotechnology

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is based in San Diego, California.

zentalis.com ↗

Background via Yahoo Finance — informational, not part of the verdict.

Grade verdict

Weak — low conviction, small size or skip

SMC — Top Down

Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.

TimeframeBiasBars
📅 Daily BEARISH 42
⏰ 4H BEARISH 39
🕐 1H BEARISH 98
⏱ 15-Min BEARISH 130
⏲ 5-Min BULLISH 234

Momentum & Volume

Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.

-16.3%
Rate of change (10d)
4.7×
Volume vs its 20-day average
-0.23
MACD (BEARISH)
$1.49
Volume POC (today)
$1.48 – $1.51
Value area

Peer Movement

How the rest of the sector moved over the same window. Context for a price move, never a cause of one.

Peer movement computing — it will appear here on its own.

Before you act on this

The questions worth asking about any verdict on this page, answered plainly.

Is this a fatwa?

No. HTR applies published screening standards to a company's own filings and shows the result under each one. It is research, not a religious ruling. For a ruling that applies to you, ask a qualified scholar.

Why can the standards disagree?

Because they measure different things. Some divide interest-bearing debt by market cap, others by total assets, and the thresholds differ too. The same filing can clear one line and cross another. HTR shows every verdict rather than averaging them into one label.

How often is this re-screened?

Ratios are recomputed when a new filing lands, and the whole watchlist is re-screened on a rolling basis. The date on the verdict above is the last time this symbol was actually recomputed, not the last time the page was built.

Do I need to purify dividends?

If a company earns some non-permissible income, many scholars hold that the same share of any dividend should be given away. The non-permissible income figure above is the number that calculation starts from — the purification calculator finishes it, showing the filing figures behind the ratio and both the proportional and the AAOIFI per-share convention.

Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.

Compare with

Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.

Peer screening computing — it will appear here on its own.

Insider Activity (90d)

Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.

NO DATA   0 buys · 0 sells

COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE

The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.

NEUTRAL   report date 2026-11-10 · Asset managers net 914130 (-14454)

AI Summary

Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.